Kabeer Aziz

Kabeer co-founded Adjuvant Capital following his time at the Global Health Investment Fund (GHIF), where he led and helped manage the fund’s investments in Themis (now part of Merck), Univercells, Atomo Diagnostics (ASX: AT1), and Access Bio (KOSDAQ: 950130), among others. Prior to GHIF, Kabeer spent time at Metalmark Capital investing across the healthcare sector, as well as Greenhill & Co., where he advised on biopharmaceutical M&A transactions.

Kabeer is based in New York and currently serves on the Board of Directors of AN2 Therapeutics, MinervaX, Quantoom Biosciences, and Pulmocide, while also supporting Adjuvant’s engagement on the Boards of Yisheng Biopharma, and previously, Themis. He graduated with honors from the Stern School of Business at New York University.